AJANTPHARM

What Ajanta Pharma promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 10 tracked 4 delivered 5 missed 1 open
  • FY27 Total Revenue Growth went quiet said Q4 FY26 Promised: high teens (16-18%) Q1 FY27: Full-year guidance for FY27, set in the previous quarter, was not mentioned or reiterated in the Q1 call.
  • GLP-1 (Semaglutide) Revenue Start on track said Q3 FY26 Promised: Revenues to start from FY27-28 Q1 FY27: No specific update provided this quarter; timeline remains distant and the project is long-term.
  • FY26 EBITDA Margin delivered said Q1 FY26 Promised: 27% (+/-1%) Q4 FY26: Full year EBITDA margin reported at 26%, which is within the guided range.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 10 tracked commitments for Ajanta Pharma — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens